Kenneth J. Hillan, MB ChB, FRCS, FRCPath, Curriculum Vitae, September 2014

ADDRESS:	[redacted]
TELEPHONE:	[redacted]
E-MAIL:	[redacted]
DATE OF BIRTH:	[redacted]
NATIONALITY:	[redacted]

LANGUAGES:	English (native) and French
UNIVERSITY EDUCATION:	Faculty of Medicine University of Glasgow, 1978-83
PROFESSIONAL QUALIFICATIONS:	MB ChB, July 1983 Fellow of the Royal College of Surgeons UK, FRCS, January 1989 Fellow of the Royal College of Pathologists UK, FRCPath, November 1993

Employment History

Current Position:

October 2011 – Date CEO Achaogen

April 2011 – Date CMO Achaogen

About Achaogen:
Achaogen is a private biopharmaceutical company developing treatments for life-threatening infections caused by multi-drug resistant (MDR) Gram-negative bacteria, an area of critical unmet medical need.

Company Milestones Achieved in 2013-14:

Closed $25M Series D financing raise.
Completed $83M IPO March 2014

Award of a $60M contract option from the Biomedical Advanced Research and Development Authority (BARDA). This supports a global Phase 3 study of plazomicin in treating patients with serious gram-negative bacterial infections due to Carbapenem Resistant Enterobacteriaceae (CRE).

FDA Special Protocol Assessment agreement for a Phase 3 clinical trial of plazomicin in patients with serious multi-drug resistant (MDR) gram-negative bacterial infections.

FDA approval of Investigational Device Exemption (IDE) for use of the plazomicin assay in the Phase 3 study.

Initiated plazomicin Phase 3 study, Q1 2014

June 2014 – Date Member of the Board of Directors of Relypsa, Inc. (RLYP)

Officer Positions at Genentech, post-acquisition of Genentech by Roche:

April 2010-April 2011 Senior Vice President and Head of Roche Product Development, Asia Pacific

Brief description: Roche Product Development head in Asia Pacific (AP), including leadership of product development offices in Shanghai, Beijing and Guangzhou. Responsible for the overall development strategy in AP, Development Chair Committee chair for China and AP regional trials.

July 2009-April 2010 Senior Vice President Clinical Development, Inflammation and Head of the Inflammation Disease Biology Leadership Team

Officer Positions at Genentech

2006 – July 2009 Vice President Immunology, Tissue Growth and Repair (ITGR)

Brief description: Head of clinical development from Early Development, pre-IND, through Post Marketing and biomarkers (lab based and clinical) for all non-oncology programs at Genentech]. Accountable for oversight of non-oncology Product Development Pipeline and Marketed Products as follows:

Immunology

Rituxan® (Rituximab), Xolair® (Omalizumab)

Ophthalmology

Lucentis® (Ranibizumab)

Metabolism and Specialty Care

Activase® (Alteplase), Cathflo® Activase® (Alteplase), Nutropin® [somatropin], TNKase®, (Tenecteplase), Pulmozyme® (dornase alfa)

2003-2006 Vice President, Development Sciences

Brief description: Oversight of the following functional areas - PKPD, Clinical Pharmacology, Bioanalytical assays, Safety Assessment (Tox & Tox Path), Research Pathology, Lab based Biomarkers, Early Development Teams and Exploratory Clinical Development (non-oncology).

2000–2003 Vice President Research Operations and Pathology, Research

Executive Leadership Roles:

- 2010-2011 Chair Roche: Chugai Development Committee & member Roche: Chugai Joint Commercial Committee
- 2009-2010: Leader of the Roche Inflammation Disease Biology Leadership Team (Research through Commercial)
- 2009-2011: Roche Personalized Healthcare Steering Committee
- 2008-2009: Co-Chair, Genentech's Late Stage Portfolio Committee - decision maker for portfolio investments and trade-offs
- 2006-Date: Executive Sponsor and Chair, Development Review Committee
- 1999-2006: Member, Genentech Research Review Committee
- 2007-2009: Member, Genentech Healthcare Compliance Committee
- 2007-2009: Member, Genentech Product Safety Committee
- 2006-2009: Member or Chair of multiple JDC and JCCs (with Roche, Novartis, Biogen-IDEC)
- 2004-2007: Member, Genentech Capital Governance Committee (all major capital investment programs)
- 2003-2006: Member, Genentech 401K Committee
- 2008-2010: Member, Genentech Access to Care Foundation (GATCF)
- 2008-2010: Chair, Clinical Advisory Board, GATCF
- 2009-2010: Executive member, Genentech Foundation
- 2008-2010: Executive sponsor Genentech Women's Professionals

Executive Leadership of Corporate Initiatives – examples of those led or co-led:

- ***Companion Diagnostics*** – resulted in creation of new scientific, development and commercial groups to support inclusion of companion diagnostic programs for all of Genentech's pipeline programs from Late Stage Research through Launch.

- ***Antibodies for Infectious Disease*** – resulted in formation of a new therapeutic area with new investment in scientific and clinical groups.

- ***Decision Making*** – resulted in implementation of a single accountable decision making model across Genentech.

Prior Positions at Genentech:

August 1994-1996	Visiting Scientist, Research, Genentech
August 1996-2010	Scientist, Department of Pathology, Research Director / Senior Director of Pathology, Research

Prior Clinical Experience:

Aug 1983 - Jul 1984	Junior House Officer in Surgery, Victoria Infirmary and in Medicine, University Department of Medicine, Western Infirmary, Glasgow, UK
Aug 1984 - Jul 1985	Medical Research Council French Exchange Fellow, Centre de Chirurgie Digestive / INSERM U9 St. Antoine Hospital, Paris, France

Aug 1985 - Jul 1988	Cruden Fellow and Surgical Registrar West of Scotland Surgical Rotation, University Department of Surgery, Western Infirmary, Glasgow, UK
Aug 1988 - July 1992	Registrar / Senior Registrar in Pathology, University Department of Pathology, Western Infirmary, Glasgow, UK
July 1992 - July 1994	Lecturer and Senior Registrar, University Department of Pathology, Glasgow, UK

Postgraduate Awards:

- MRC French Exchange Fellow 1984-5, INSERM U9, St. Antoine Hospital, Paris, France.
- Cruden Research Fellow, University Department of Surgery, Western Infirmary, Glasgow, 1986-87.
- Scottish Home and Health Department Fellow, University Department of Surgery, Western Infirmary, Glasgow, 1986-87.
- "Hepatocyte growth factor and its receptor c-met: an assessment of their mitogenic and morphogenic roles in liver disease", 1992-3 Scottish Hospitals Endowment Research Trust
- Wellcome Foundation grant for “Transplantation of human hepatocytes into SCID mice",1994

Selected External Presentations 2005-2008

- Molecular targeted therapies for cancer: role of the pathologist. Japanese Society of Pathology, Yokahama, Japan. April 2005
- Correlations of mutations in EGFR and KRAS with clinical outcomes in non-small cell lung cancer. Cold Spring Harbor 70th symposium, Molecular Approaches to Controlling Cancer, Cold Spring Harbor Laboratories. June 2005
- Selecting patients for targeted therapies. Stanford University Cancer Biology Seminar Series, Stanford University. November 2005
- Selecting patients for targeted cancer therapies. Graduate Cancer Biology Course, University of Chicago, Chicago. March 2006
- Molecular targeted therapy of colorectal cancer. International Academy of Pathology, Montreal, Canada. September 2006
- Selecting patients for targeted therapy in lung cancer. NCRI UK, Birmingham, UK. October 2006
- Patient selection for Herceptin therapy. Cancer Colloquia, University of St Andrews, St Andrews, UK. November 2006
- Personalized therapy and molecular pathology. Pathological Society of Great Britain and Ireland, Glasgow, UK. June 2007
- Tackling Angiogenesis. Pathological Society of Great Britain and Ireland, Glasgow, UK. June 2007
- Predictive and prognostic biomarker workshop co-lead. Cancer Research UK, Lincolns Inn Field, London UK. January 2008

Publications:

1) Hannoun L, Levy E, Beuzit JM, Masini JP, Bahini A, **Hillan KJ**. Les peritonites d'origine sus-mesocolique 217 cas. Ann Chir 1985: 39, 517-3

2) Nordlinger B, Wang SR, Bouma ME, Verthier N, **Hillan KJ**, Delelo R, Infante R. European Surgical Research 1987, 19: 381-2

3) **Hillan KJ**, Nordlinger B, Ballet F, Putz JP, Infante R. The healing of colonic anastomoses in the rat after early intraperitoneal chemotherapy. Journal of Surgical Research 1988: 44, 166-71

4) **Hillan KJ**, Burt AD, George WD, MacSween RNM, Bradley JAB. Intrasplenic hepatocyte transplantation in rats with experimental liver injury. Journal of Pathology 1989: 159, 67-73

5) **Hillan KJ**, MacSween RNM, McNicol AM. The demonstration of rat albumin mRNA with RNA probes labelled with digoxigenin. Digest 1990: 6, 1-2

6) Holyoake TL, **Hillan KJ**, Lucie NP, Acute cardiotoxicity after daunorubicin in acute myeloid leukaemia. Leukaemia and Lymphoma 1991: 3, 305-7

7) **Hillan KJ**, Johnson PJ, Morton R. Referral of minor surgical specimens for histology: the impact of the new GP contract. British Medical Journal, 1991, 303: 1180

8) Johnson SJ, **Hillan KJ**, Hines JE, Ferrier RK, Burt AD. Proliferation and phenotypic modulation of perisinusoidal (Ito) cells following acute liver injury: temporal relationship with TGFß-1 expression. Cellular and Molecular aspects of Cirrhosis. Eds. Clemont B and Guillouzo A. INSERM/Libbey Eurotext Ltd, 1992; 219-22

9) Penman ID, El-Omar E, McGregor JR, **Hillan KJ**, O'Dwyer PJ and McColl KEL. Omeprazole inhibits azoxymethane-induced colorectal carcinogenesis in rats. Gut, 1993, 34: 1159-65

10) McLean MA, Cameron AD, Cumming GP, Murphy Karl, Mills P, **Hillan KJ**. Recurrence of acute fatty liver of pregnancy. British Journal of Obstetrics and Gynaecology, 1994, 101: 453-4

11) Doughty SE, Ferrier RK, **Hillan KJ**, Roberts DG. The effects of Zeneca ZD8731, an angiotensin II antagonist, on renin expression by juxtaglomerular cells in the rat; Comparison of protein and mRNA expression as detected by immunohistochemistry and in situ hybridization. Toxocologic Pathology, 1995, 23: 256-61

12) Bird GLA, Tibbs CJ, Orton D, **Hillan KJ**, MacSween RNM, Williams R, Mills PR. Does hepatitis C contribute to liver injury in alcohol abusers in the West of Scotland? European Journal of Gastroenterology and Hepatology, 1995, 7: 161-3

13) Bird GLA, Spence E, **Hillan KJ**, MacSween RNM, Frame D, Yap P, Dow B, McOmish F, Mills PR. Genotypic variation and clinical characteristics of chronic hepatitis C detected at blood donor screening. Journal of Viral Hepatitis, 1995, 2(5): 261-5

14) **Hillan KJ**, Logan MC, Ferrier RK, Bird GLA, Bennett GL, McKay IC and MacSween RNM. Hepatocyte proliferation and serum hepatocyte growth factor levels in patients with alcoholic hepatitis. Journal of Hepatology 1996, 24(4), 385-90

15) Nagy J, Curry GW, **Hillan KJ**, McKay IC, Purushotham AD, George WD. Hepatocyte growth factor/ Scatter factor, angiogenesis and tumour cell proliferation in primary breast cancer. Journal of the Breast 1995.

16) Nagy J, Curry GW, **Hillan KJ**, McKay IC, Purushotham AD, George WD. Hepatocyte growth factor/ Scatter factor and c-met expression in primary breast cancer. Surgical Oncology 1996, 5(1):15-21

17) Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea S, Powell-Braxton L, **Hillan KJ**, Moore MW. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996, 380, 439-442

18) McCruden EAB, **Hillan KJ**, MacKay IC, Cassidy M. Hepatitis virus infection and liver disease in injecting drug users dying suddenly. Journal of Clinical Pathology 1996, 49(7):552-5

19) Schwall RH, Chang LY, Godowski PJ, Kahn DW, **Hillan KJ**, Bauer KD, Zioncheck TF. Heparin induces dimerization and confers proliferative activity onto the HGF antagonists NK1 and NK2. J Cell Biol 1996, 133(3):709-18

20) Borgstrom P. **Hillan KJ.** Sriramarao P. Ferrara N. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Research. 1996, 56(17):4032-9

21) Viney JL. Jones S. Chiu HH. Lagrimas B. Renz ME. Presta LG. Jackson D. **Hillan KJ.** Lew S. Fong S. Mucosal addressin cell adhesion molecule-1: a structural and functional analysis demarcates the integrin binding motif. Journal of Immunology. 1996, 157(6):2488-97

22) Burr AW, **Hillan KJ**, McLaughlin KE, Ferrier R, Chapman C, Mathew J, Burt AD Hepatocyte growth factor levels in liver and serum increase during chemical hepatocarcinogenesis. Hepatology. 1996, 24(5):1282-7

23) Ferrara N. Chen H. Davis-Smyth T. Gerber HP. Nguyen TN. Peers D. Chisholm V. **Hillan KJ**. Schwall RH. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nature Medicine. 1998, 4(3):336-40

24) Borgstrom P. Bourdon MA. **Hillan KJ.** Sriramarao P. Ferrara N. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. 1998, Prostate. 35(1):1-10

25) Zhang D. Sliwkowski MX. Mark M. Frantz G. Akita R. Sun Y. **Hillan K**. Crowley C. Brush J. Godowski PJ. Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and activates ErbB4. PNAS 1997, 94(18):9562-7

26) Pennica D, Swanson TA, Welsh JW, Roy MA, Lawrence DA, Lee J, Brush J, Taneyhill LA, Deuel B, Lew M, Watanabe C, Cohen RL, Melhem MF, Finley GG, Quirke P, Goddard AD, **Hillan KJ**, Gurney AL, Botstein D, Levine AJ. WISP genes are members of the connective tissue growth factor family that are up-regulated in Wnt-1-

transformed cells and aberrantly expressed in human colon tumors. PNAS 1998 95: 14717-14722

27) Pitti RM, Marsters SA, Lawrence DA, Roy M, Dowd P, Huang A, Donahue CJ, Baldwin D, Godowski P, Wood WI, Gurney A, **Hillan KJ**, Goddard AD, Botstein D, Ashkenazi A. Genomic amplification of a novel decoy receptor for Fas ligand in lung and colon cancer. Nature 1998 396: 699 – 703

28) Gerber HP, **Hillan KJ**, Ryan AM, Kowalski J, Chen J, Chen H, Wright BD, Radke F, Aguet M, Ferrara N. VEGF determines organ size and is required for survival in neonatal mice. Development, 1999 126:1149-59

29) Borgstrom P, Gold DP, **Hillan KJ**, Ferrara N. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res. 1999 5B:4203-14

30) Xie MH, Holcomb I, Deuel B, Dowd P, Huang A, Vagts A, Foster J, Liang J, Brush J, Gu Q, **Hillan K**, Goddard A, Gurney AL. FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine. 1999 10: 729-35

31) Shimkets RA, Lowe DG, Tai JT, Sehl P, Jin H, Yang R, Predki PF, Rothberg BE, Murtha MT, Roth ME, Shenoy SG, Windemuth A, Simpson JW, Simons JF, Daley MP, Gold SA, McKenna MP, **Hillan K**, Went GT, Rothberg JM. Gene expression analysis by transcript profiling coupled to a gene database query. Nat Biotechnol. 1999 8:798-803

32) **Hillan KJ**, Hagler KE, MacSween RNM, Ryan AM, Renz ME, Chiu HH, Ferrier RK, Bird GL, Amar P. Dhillon AP, Ferrell LD Fong. Expression of the mucosal vascular addressin, MAdCAM-1, in inflammatory liver disease. Liver. 1999 19: 509-18

33) Sehl PD, Tai JT, **Hillan KJ**, Brown LA, Goddard A, Yang R, Jin H, Lowe DG. Application of cDNA microarrays in determining molecular phenotype in cardiac growth, development, and response to injury. Circulation. 101(16):1990-9, 2000 Apr 25.

34) Koeppen HK, Wright BD, Burt AD, Quirke P, McNicol AM, Dybdal NO, Sliwkowski MX, **Hillan KJ**. Overexpression of HER2/neu in solid tumours: an immunohistochemical survey. Histopathology. 2001 Feb;38(2):96-104

35) Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, **Hillan K**, Totpal K, DeForge L, Schow P, Hooley J, Sherwood S, Pai R, Leung S, Khan L, Gliniak B, Bussiere J, Smith CA, Strom SS, Kelley S, Fox JA, Thomas D, Ashkenazi A. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med. 2001 Apr;7(4):383-5

36) LeCouter J, Kowalski J, Foster J, Hass P, Zhang Z, Dillard-Telm L, Frantz G, Rangell L, DeGuzman L, Keller GA, Peale F, Gurney A, **Hillan KJ**, Ferrara N. Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature. 2001 Aug 30;412(6850):877-84

37) Genomic Pathology – A New Frontier. Journal of Pathology Annual Review Edition 2001, Editors **Hillan KJ** and Quirke P.

38) **Hillan KJ**, Quirke P. Preface to genomic pathology--a new frontier. J Pathol. 2001 Sep;195(1):1-2

39) Lewis F, Maughan NJ, Smith V, **Hillan K**, Quirke P. Unlocking the archive--gene expression in paraffin-embedded tissue. J Pathol. 2001 Sep;195(1):66-71

40) Frantz GD, Pham TQ, Peale FV Jr, **Hillan KJ**. Detection of novel gene expression in paraffin-embedded tissues by isotopic in situ hybridization in tissue microarrays. J Pathol. 2001 Sep;195(1):87-96

41) Cai L, Yin JP, Starovasnik MA, Hogue DA, **Hillan KJ**, Mort JS, Filvaroff EH. Pathways by which interleukin 17 induces articular cartilage breakdown in vitro and in vivo. Cytokine. 2001 Oct 7;16(1):10-21.

42) Ross S, Spencer SD, Holcomb I, Tan C, Hongo J, Devaux B, Rangell L, Keller GA, Schow P, Steeves RM, Lutz RJ, Frantz G, **Hillan K**, Peale F, Tobin P, Eberhard D, Rubin MA, Lasky LA, Koeppen H.
Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res. 2002 May 1;62(9):2546-53

43) Nicholes K, Guillet S, Tomlinson E, **Hillan K**, Wright B, Frantz GD, Pham TA, Dillard-Telm L, Tsai SP, Stephan JP, Stinson J, Stewart T, French DM. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic. Am J Pathol. 2002 Jun;160(6):2295-307

44) LeCouter J, Moritz DR, Li B, Phillips GL, Liang XH, Gerber HP, **Hillan KJ**, Ferrara N. Angiogenesis independent endothelial protection of liver: role of VEGFR-1. Science. 2003 Feb 7;299(5608):890-3

45) LeCouter J, Lin R, Tejada M, Frantz G, Peale F, **Hillan KJ**, Ferrara N. The endocrine-gland-derived VEGF homologue Bv8 promotes angiogenesis in the testis: Localization of Bv8 receptors to endothelial cells. Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2685-90. Epub 2003 Feb 25

46) LeCouter J, Lin R, Frantz G, Zhang Z, **Hillan K**, Ferrara N. Mouse endocrine gland-derived vascular endothelial growth factor: a distinct expression pattern from its human ortholog suggests different roles as a regulator of organ-specific angiogenesis. Endocrinology. 2003 Jun;144(6):2606-16

47) Jubb AM, Landon TH, Burwick J, Pham TQ, Frantz GD, Cairns B, Quirke P, Peale FV, **Hillan KJ**. Quantitative analysis of colorectal tissue microarrays by immunofluorescence and in situ hybridization. J Pathol. 2003 Aug;200(5):577-88

48) Oakley F, Trim N, Constandinou CM, Ye W, Gray AM, Frantz G, **Hillan K**, Kendall T, Benyon RC, Mann DA, Iredale JP. Hepatocytes express nerve growth factor during liver injury: evidence for paracrine regulation of hepatic stellate cell apoptosis. Am J Pathol. 2003 Nov;163(5):1849-58

49) Sauter G, Simon R, **Hillan K**. Tissue microarrays in drug discovery. Nat Rev Drug Discov. 2003 Dec;2(12):962-72

50) Parker LH, Schmidt M, Jin SW, Gray AM, Beis D, Pham T, Frantz G, Palmieri S, **Hillan K**, Stainier DY, De Sauvage FJ, Ye W. The endothelial-cell-derived secreted factor Egfl7 regulates vascular tube formation. Nature. 2004 Apr 15;428(6984):754-8

51) Ferrara N, **Hillan KJ**, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004 May;3(5):391-400

52) Jubb AM, Pham TQ, Hanby AM, Frantz GD, Peale FV, Wu TD, Koeppen HW, **Hillan KJ**. Expression of vascular endothelial growth factor, hypoxia inducible factor-1 alpha, and carbonic anhydrase IX in human tumours. J Clin Pathol. 2004 May;57(5):504-12

53) Zhang Y, Eberhard DA, Frantz GD, Dowd P, Wu TD, Zhou Y, Watanabe C, Luoh SM, Polakis P, **Hillan KJ**, Wood WI, Zhang Z. GEPIS--quantitative gene expression profiling in normal and cancer tissues. Bioinformatics. 2004 Oct 12;(15):2390-8

54) Hall PA, Jung K, **Hillan KJ**, Russell SE. Expression profiling the human septin gene family. J Pathol. 2005 Jul;206(3):269-78

55) Ferrara N, **Hillan KJ,** Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem & Biophys Res Commun. 2005 Jul 29;333(2):328-35

56) Ince WL, Jubb AM, Holden SN, Holmgren EB, Tobin P, Sridhar M, Hurwitz HI, Kabbinavar F, Novotny WF, **Hillan KJ**, Koeppen H. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J. Nat. Cancer Inst. 2005 Jul 6;97(13):981-9

57) Scott M, Hyland PL, McGregor G, **Hillan KJ**, Russell SE, Hall PA. Multimodality expression profiling shows SEPT9 to be overexpressed in a wide range of human tumours. Oncogene 2005 Jul 7;24(29):4688-700

58) Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Janne PA, Januario T, Johnson DH, Klein P, Miller VA, Ostland MA, Ramies DA, Sebisanovic D, Stinson JA, Zhang YR, Seshagiri S, **Hillan KJ**. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol. 2005;23(25):5900-9

59) Hall PA, Todd CB, Hyland PL, McDade SS, Grabsch H, Dattani M, **Hillan KJ**, Russell SE. The septin-binding protein anillin is overexpressed in diverse human tumors. Clin Cancer Res. 2005 Oct. 1;11(19 Pt 1):6780-6

60) Jubb A, **Hillan K**. Expression of HIF-1 alpha in human tumours. J. Clin. Pathol. 2005 Dec;58(12):1344

61) Amler LC, Goddard AD, **Hillan KJ.** Predicting clinical benefit in non-small-cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors. Cold Spring Harbor Symposia on Quantitative Biology 2005;70:483-8

62) Jubb AM, Hurwitz HI, Bai W, Holmgren EB, Tobin P, Guerrero AS, Kabbinavar F, Holden SN, Novotny WF, Frantz GD, **Hillan KJ,** Koeppen H. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J. Clin. Oncol. 2006;24(2):217-27

63) Scott M, McCluggage WG, **Hillan KJ,** Hall PA, Russell SE. Altered patterns of transcription of the septin gene, SEPT9, in ovarian tumorigenesis. Internat. J. Cancer 2006 Mar 1;118(5):1325-9

64) Jubb AM, Pham TQ, Frantz GD, Peale FV Jr, **Hillan KJ**. Quantitative in situ hybridization of tissue microarrays. Methods in Mol. Biol. 2006;326:255-64

65) Jubb AM, Chalasani S, Frantz GD, Smits R, Grabsch HI, Kavi V, Maughan NJ, **Hillan KJ**, Quirke P, Koeppen H. Achaete-scute like 2 (ascl2) is a target of Wnt signaling and is upregulated in intestinal neoplasia. Oncogene 2006 June 8;25(24):3445-57

66) Peters BA, Kan Z, Sebisanovic D, Pujara K, Wang Z, Hong P, Chow B, Stinson J, Carlton VE, Pham TQ, Stern H, Waring P, **Hillan KJ**, Eberhard DA, de Sauvage F, Zheng J, Faham M, Seshagiri S. Highly efficient somatic-mutation identification using Escherichia coli
mismatch-repair detection. Nat Methods. 2007 Sep;4(9):713-5.

67) Jubb AM, Miller KD, Harris AL, Chen D, Reimann JD, Cobleigh MA, Rugo HS, Schmidt M, Langmuir VK, Hillan KJ, Chen DS, Koeppen H. Impact of Exploratory Biomarkers on the Treatment Effect of Bevacizumab in Metastatic Breast Cancer. Clinical Cancer Research. 2011 Jan 15;17(2):372-81

Named Inventor on US Patents:

Selected list of US Patent # Title

1 7,344,880 Nucleic acid encoding PRO9912 polypeptides
2 7,307,153 Antibodies that bind PRO9912
3 7,291,712 Interleukin-8 homologous polypeptides and therapeutic uses thereof

4 7,282,562 Compositions and methods for the treatment of immune related diseases
5 7,250,264 Diagnosis and treatment of hepatic disorders
6 7,208,308 Secreted and transmembrane polypeptides and nucleic acids encoding the same
7 7,196,165 PRO363 polypeptides
8 7,189,529 PRO792 nucleic acids
9 7,164,001 Compositions and methods for the treatment of immune related diseases
10 7,151,160 Secreted and transmembrane polypeptides and nucleic acids encoding the same
11 7,135,334 PRO20044 nucleic acids
12 7,132,283 PRO273 polypeptides
13 7,098,312 Secreted and transmembrane polypeptides and nucleic acids encoding the same
14 7,094,567 Secreted and transmembrane polypeptides and nucleic acids encoding the same
15 7,090,845 Diagnosis and treatment of hepatic disorders
16 7,087,738 Secreted and transmembrane polypeptides and nucleic acids encoding the same
18 7,074,592 Secreted and transmembrane polypeptides nucleic acid encoding
19 7,041,805 Secreted and transmembrane polypeptides and nucleic acids encoding the same
20 7,034,123 Anti-PRO1347 antibodies
21 7,033,786 Pro1340 nucleic acids
22 7,029,874 Secreted and transmembrane polypeptides and nucleic acids encoding the same
23 7,026,449 Secreted and transmembrane polypeptides and nucleic acids encoding the same
24 7,026,448 Secreted and transmembrane polypeptides and nucleic acids encoding the same
25 7,018,837 Nucleic acids encoding secreted polypeptides that stimulate release of proteoglycans from cartilage
26 6,974,689 Nucleic acid encoding PRO211 polypeptides
27 6,972,325 PRO273 polypeptides
28 6,965,015 Secreted and transmembrane polypeptides and nucleic acids encoding the same
29 6,965,011 Secreted and transmembrane polypeptides and nucleic acids encoding the same
30 6,946,262 Secreted and transmembrane polypeptides and nucleic acids encoding the same
31 6,936,436 Secreted and transmembrane polypeptides and nucleic acids encoding the same
32 6,936,254 Method of inducing fetal hemoglobin synthesis
33 6,908,993 Secreted and transmembrane polypeptides and nucleic acids encoding the same
34 6,878,807 Secreted and transmembrane polypeptides and nucleic acids encoding the same
35 6,828,146 Nucleic acid encoding PRO229 polypeptides

36 6,723,535 Secreted and transmembrane polypeptides and nucleic acids encoding the same
37 6,664,376 Secreted and transmembrane polypeptides and nucleic acids encoding the same
38 6,635,468 Secreted and transmembrane polypeptides and nucleic acids encoding the same
39 6,579,520 IL-17 related mammalian cytokine polypeptides (IL-17E)
40 6,569,645 IL-17 homologous polypeptides and therapeutic uses thereof
41 6,551,822 NL4 tie ligand homologue
42 6,413,770 NL4 tie ligand homologue nucleic acid
43 6,387,657 WISP polypeptides and nucleic acids encoding same
44 6,350,450 TIE ligand homologue antibody
45 6,348,351 TIE receptor tyrosine kinase ligand homologues
46 6,099,841 Hepatocyte growth factor receptor agonists and uses thereof
47 6,074,873 Nucleic acids encoding NL-3

Committee on Energy and Commerce
U.S. House of Representatives

Witness Disclosure Requirement - "Truth in Testimony"
Required by House Rule XI, Clause 2(g)

1. Your Name: Kenneth J. Hillan		
2. Are you testifying on behalf of the Federal, or a State or local government entity?	**Yes**	**No** X
3. Are you testifying on behalf of an entity that is not a government entity?	**Yes** X	**No**
4. Other than yourself, please list which entity or entities you are representing: Achaogen, Inc.		

5. Please list any Federal grants or contracts (including subgrants or subcontracts) that you or the entity you represent have received on or after October 1, 2011:

Achaogen has received funding from the following grants and contracts after October 1, 2011

BARDA - HHS010020100046C 9/19/2010-9/18/2015
ACHN-490: a Novel Broad Spectrum Next-generation Aminoglycoside Antibiotic for the Treatment of Resistant Threat Agents
Amount realized to date: $51,432,348

NIAID - HHSN272200800043C 9/1/2008-8/31/2013 (contract complete)
Novel Aminoglycoside Agents for Treatment of Antimicrobial Resistant Category A and B Bacterial Infections
Amount realized: $21,069,782

DOD - W81XWH-12-2-0040 5/7/2012-5/6/2013 (contract complete)
A First-in-Human Phase 1 Clinical Study of ACHN-975, a First-in-Class Agent Being Developed for the Treatment of Serious Multidrug-Resistant Gram-Negative Bacterial Infections
Amount realized: $2,499,000

DOD - HDTRA1-07-C-0079 6/15/2007-6/15/2012 (contract complete)
Novel Broad-Spectrum Therapeutics Against Gram-Negative Bacterial Threat Agents
Amount realized: $33,480,41

NIAID - 1R21AI113572-01 08/01/2014 – 07/31/2015
Structure and property driven optimization of fatty acid synthesis inhibitors for Gram-negative antibiotics
Amount awarded: $407,104

6. If your answer to the question in item 3 in this form is "yes," please describe your position or representational capacity with the entity or entities you are representing:

Chief Executive Officer

	Yes	No
7. If your answer to the question in item 3 is "yes," do any of the entities disclosed in item 4 have parent organizations, subsidiaries, or partnerships that you are not representing in your testimony?		X

8. If the answer to the question in item 3 is "yes," please list any Federal grants or contracts (including subgrants or subcontracts) that were received by the entities listed under the question in item 4 on or after October 1, 2011, that exceed 10 percent of the revenue of the entities in the year received, including the source and amount of each grant or contract to be listed:

Achaogen has received funding from the following grants and contracts after October 1, 2011

BARDA - HHS010020100046C 9/19/2010-9/18/2015
ACHN-490: a Novel Broad Spectrum Next-generation Aminoglycoside Antibiotic for the Treatment of Resistant Threat Agents
Amount realized to date: $51,432,348

NIAID - HHSN272200800043C 9/1/2008-8/31/2013 (contract complete)
Novel Aminoglycoside Agents for Treatment of Antimicrobial Resistant Category A and B Bacterial Infections
Amount realized: $21,069,782

DOD - W81XWH-12-2-0040 5/7/2012-5/6/2013 (contract complete)
A First-in-Human Phase 1 Clinical Study of ACHN-975, a First-in-Class Agent Being Developed for the Treatment of Serious Multidrug-Resistant Gram-Negative Bacterial Infections
Amount realized: $2,499,000

DOD - HDTRA1-07-C-0079 6/15/2007-6/15/2012 (contract complete)
Novel Broad-Spectrum Therapeutics Against Gram-Negative Bacterial Threat Agents
Amount realized: $33,480,411

NIAID - 1R21AI113572-01 08/01/2014 – 07/31/2015
Structure and property driven optimization of fatty acid synthesis inhibitors for Gram-negative antibiotics
Amount awarded: $407,104

9. Please attach your curriculum vitae to your completed disclosure form.

Signature: [redacted] **Date:** 9/17/14